Browsing Category
Pharmaceutical
Unregulated Antibiotic Use in Animal Research Poses Threat to Human Health Study Finds
A recent study has highlighted concerning practices in animal research facilities that may worsen the global crisis of antimicrobial resistance. Published in the journal *Plos One*, the research indicates that antibiotic use in laboratory…
Revolutionary Weight Loss Jabs Have The Potential To Treat Cancer, Arthritis, Alzheimer’s, and…
The pharmaceutical industry stands on the cusp of a major transformation as revolutionary weight-loss injections demonstrate potential far beyond their initial scope. Semaglutide, marketed under brands like Ozempic and Wegovy, has shown…
GSK and Other Drugmakers Granted Hearing in Zantac Cancer Litigation Case
The Delaware Supreme Court has agreed to hear an appeal by GSK and other pharmaceutical giants, including Pfizer, Sanofi, and Boehringer Ingelheim, in their bid to halt more than 70,000 lawsuits alleging that the discontinued heartburn…
Adaptive Deep Brain Stimulation Offers Hope for Better Parkinson’s Symptom Control
In a groundbreaking pilot study, researchers have introduced an innovative approach to deep brain stimulation (DBS) that may greatly enhance the lives of individuals with Parkinson's disease. This technique, referred to as "adaptive" DBS,…
AI Revolutionises Drug Discovery Saving Time and Lives for Pharmaceutical Giants
In a world where numerous industries are reevaluating the transformative potential of artificial intelligence (AI), the pharmaceutical sector is already experiencing revolutionary changes in drug discovery. Companies like GSK and…
AstraZenecas 450M Pound Vaccine Plant Investment at Risk Amid Treasury Budget Cuts
The fate of AstraZeneca's planned £450 million investment in a vaccine manufacturing facility in northwest England hangs in the balance as the Treasury, under the leadership of Chancellor Rachel Reeves, reviews spending decisions made by…
NHS Launches Antibiotic Subscription Scheme with Pharmaceutical Industry
The National Health Service (NHS) has announced a groundbreaking initiative to tackle the growing threat of antimicrobial resistance (AMR) by partnering with the pharmaceutical industry. The NHS will negotiate fixed-fee contracts with…
Pfizer continues to test a once-aday weight loss pill
A pharmaceutical giant will test an experimental treatment in response to the surge in demand for obesity treatments
Pfizer has accelerated the trials of a weight loss pill that can be taken once a day. Drug makers are racing to create…
Arecor Therapeutics PLC: A Rising Star in Diabetes and Obesity Innovations
Arecor Therapeutics PLC, listed on AIM as AREC, has been making waves in the healthcare industry with its innovative approach to diabetes and obesity treatments. In a recent interview with Proactive Investor's Stephen Gunnion, CEO Sarah…
After Macron’s charm offensive, UK pharmaceutical giants commit £430m to France
After Emmanuel Macron's charm offensive, the two largest pharmaceutical companies in Britain have committed £430m to France.
AstraZeneca, GSK and other pharmaceutical companies have pledged to upgrade their facilities within the country…
FDA Grants Rare Pediatric Disease Designation to Imaging Biometrics’ Lead Drug Candidate…
Imaging Biometrics, a subsidiary of IQ-AI Ltd, has recently made a significant announcement regarding its lead drug candidate, IB-003. The US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to…
Shield Therapeutics Reports Nearly Tripled Revenues in 2023
Shield Therapeutics, a pharmaceutical company focusing on iron deficiency treatments, has reported a significant increase in revenues for the year 2023. The company's sales of its Accrufer/Feraccru iron deficiency treatment surged in the US…
Sir John Bell, tsar of life sciences, believes that London is not the best place to raise funds.
Sir John Bell, one of Britain's leading life sciences leaders, warned of an imminent exodus of pharmaceutical companies from London, calling the City "a bad place to raise funds".
Sir John, a veteran of the industry known for his crucial…
Ireland’s life sciences industry is healthy, leaving the UK sickly.
Novo Nordisk's attempts to alleviate global shortages of the "wonder drug", which it claims to be a weight-loss miracle, have led them to a businesspark on the outskirts Dublin.
Last year, the Danish group overtook LVMH (the French…
Novo Nordisk shares reach record highs as obesity drug boom drives share prices up
Novo Nordisk's shares reached a new record high following the Danish company's report of soaring sales for its obesity and diabetic drugs Wegovy, and Ozempic. This pushed its market value over $500bn. It also cemented its position as…
Debt-laden Haleon kisses goodbye to ChapStick
Haleon sold ChapStick for more than $500m as it sought to reduce its debts while also boosting its stock price.
The FTSE-100 company has agreed that it will sell its lip balms to Suave Brands for approximately $430 million cash plus a…
Syntara’s $10M Raise: Fueling Drug Development
Syntara's $10M capital raise is propelling its drug development strategy into a new era.
In this exclusive interview, CEO Gary Phillips unveils the transformative steps taken by Syntara Ltd, from its rebranding efforts to the strategic…
Walgreen, Boots’ owner, explores London listing for high-street chain
Boots, the US-owned high street pharmacy chain, is considering a £7bn UK IPO. This could give London's struggling stock market a needed boost.
Walgreens Boots Alliance, which abandoned its plan to sell Boots two years ago, is believed to…